VMAT1 Gene Polymorphism Detection for Mood Disorder Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating mood disorders and schizophrenia are inadequate, as they do not effectively address the genetic complexities of these conditions, leading to incomplete symptom relief and long-term suffering for many patients.
Innovation Solution
Detecting polymorphisms in the vesicular monoamine transporter 1 (VMAT1) gene or its haplotypes to determine predisposition to mood disorders and schizophrenia, and using nucleic acids encoding VMAT proteins or modulating their expression to treat these conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatment methods are used for mood disorders and schizophrenia, then treatment can be administered, but symptom relief is incomplete and long-term suffering continues
Solution Approach 1:
The patent applies parameter changes by identifying specific genetic polymorphisms (VMAT1 gene variants) as biomarkers to personalize treatment parameters. By detecting these genetic parameters, the treatment can be tailored to individual patients' genetic profiles, thereby improving treatment effectiveness and completeness of symptom relief.
Solution Approach 2:
The patent segments the treatment approach by dividing patients into subgroups based on their VMAT1 genotype. This segmentation allows for targeted therapeutic strategies for different genetic subtypes of mood disorders and schizophrenia, improving overall treatment reliability and symptom relief.
2Measurement precision
If genetic testing for VMAT1 polymorphisms is implemented, then personalized diagnosis and treatment can be achieved, but diagnostic complexity increases
Solution Approach 1:
The patent extracts specific polymorphic sites from the VMAT1 gene as diagnostic markers. By focusing on these particular genetic variations rather than analyzing the entire genome, the method achieves high diagnostic precision while reducing the complexity of genetic testing.
Solution Approach 2:
The patent uses VMAT1 polymorphism detection as an intermediary step between general genetic screening and specific treatment selection. This intermediary approach simplifies the diagnostic process by providing a focused genetic marker that correlates with treatment response, reducing overall diagnostic complexity.
Data Source
AI summary
This invention provides: methods of determining a predisposition or susceptibility of a subject to a mood disorder, a schizophrenia, or a neuro-psychiatric disease or disorder, comprising detecting a presence of a polymorphism in a vesicular monoamine transporter 1 (VMAT1) gene or a haplotype comprising the polymorphism, and methods of treating a mood disorder, a schizophrenia, or a neuro-psychiatric disease or disorder in a subject, comprising contacting the subject with a composition that encodes a VMAT protein or modulates an expression or activity of same.